In 1923 was created Novo Nordisk, which is appeared as Corporate Investor. The main office of represented Corporate Investor is situated in the Bagsvu00e6rd. The company was established in Europe in Denmark.
For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most successful fund investment fields, there are Clinical Trials, Health Care. The fund has exact preference in some founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight TransTech Pharma, Beta Bionics, IO Biotech.
The usual things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2015. The fund is constantly included in less than 2 investment rounds annually. The higher amount of exits for fund were in 2014. This Novo Nordisk works on 9 percentage points more the average amount of lead investments comparing to the other organizations. The real fund results show that this Corporate Investor is 8 percentage points less often commits exit comparing to other companies.
The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Novo Nordisk, startups are often financed by Stafford Capital Partners, Sofinnova Partners, Gimv. The meaningful sponsors for the fund in investment in the same round are Yasuda Enterprise Development, Western Technology Investment, Sofinnova Partners. In the next rounds fund is usually obtained by RTW Investments LLC, OrbiMed, Novo Holdings.
Related Funds
| Fund Name | Location |
| 360by360 Competition | Italy, Lombardia, Milano |
| Agroecology Capital | California, Palo Alto, United States |
| ARM IoT Capital | - |
| Bering Waters Ventures | - |
| Cox Enterprises | Atlanta, Georgia, United States |
| D20 Capital | California, San Francisco, United States |
| Dow Jones | New York, New York, United States |
| Fielmann Ventures | Germany, Hamburg, Hamburg |
| Greenwoods Investment | China, Shanghai, Shanghai |
| HERi Africa | - |
| Hermitage Asset Management | - |
| Juesheng.com | China, Dongcheng, Shaanxi |
| maaiiconnect | China, Hong Kong, Kowloon |
| Makerpad | Cardiff, United Kingdom, Wales |
| PASCO | Japan, Tokyo |
| Slaight Communications | Canada, Ontario, Toronto |
| The Andan Foundation | Obwalden, Sarnen, Switzerland |
| Wells Fargo Foundation | Minneapolis, Minnesota, United States |
| xross | Chiyoda, Japan |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
The Sabi | $177K | 06 Apr 2023 | Amsterdam, Noord-Holland, The Netherlands | ||
Beta Bionics | $57M | 17 Feb 2022 | Boston, Massachusetts, United States | ||
Sundew | $1M | 24 Sep 2020 | Copenhagen, Hovedstaden, Denmark | ||
Beta Bionics | $63M | 10 Jan 2019 | Boston, Massachusetts, United States | ||
IO Biotech | $12M | 05 Jan 2016 | Capital Region of Denmark | ||
Beta Bionics | $5M | 31 Dec 2015 | Boston, Massachusetts, United States | ||
Affimed | $23M | 29 Apr 2010 | Heidelberg, Baden-Württemberg, Germany | ||
| $11M | 03 Sep 2008 | San Francisco, California, United States | |||
Pieris Pharmaceuticals | $38M | 27 Mar 2008 | Boston, Massachusetts, United States |
– Glooko, a leading provider of remote patient monitoring and chronic care management solutions including diabetes and obesity, has raised a $30m Series D round of funding.
– The financing was led by Health Catalyst Capital along with participation from existing investors Canaan Partners, Georgian, Novo Nordisk, Insulet and Mayo Clinic.
– Proceeds will be used to accelerate organic growth and strategic initiatives across the company’s broad and growing product line of advanced digital health solutions.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
The Sabi | $177K | 06 Apr 2023 | Amsterdam, Noord-Holland, The Netherlands | ||
Beta Bionics | $57M | 17 Feb 2022 | Boston, Massachusetts, United States | ||
Sundew | $1M | 24 Sep 2020 | Copenhagen, Hovedstaden, Denmark | ||
Beta Bionics | $63M | 10 Jan 2019 | Boston, Massachusetts, United States | ||
IO Biotech | $12M | 05 Jan 2016 | Capital Region of Denmark | ||
Beta Bionics | $5M | 31 Dec 2015 | Boston, Massachusetts, United States | ||
Affimed | $23M | 29 Apr 2010 | Heidelberg, Baden-Württemberg, Germany | ||
| $11M | 03 Sep 2008 | San Francisco, California, United States | |||
Pieris Pharmaceuticals | $38M | 27 Mar 2008 | Boston, Massachusetts, United States |
